Form 4: STERIS plc Director Richard Martin Steeves Reports Stock Option and Restricted Stock Unit Grants

Director Richard Martin Steeves reports the acquisition of stock options and restricted stock units in STERIS plc, including grants in lieu of fees.

Summary

• Richard Martin Steeves, a director of STERIS plc, filed a Form 4 on August 12, 2024, reporting transactions that occurred on August 8, 2024.
• Steeves acquired 1,389 stock options with an exercise price of $239.68, expiring on August 8, 2034.
• He also acquired 175 stock options with the same exercise price and expiration date, issued in lieu of $15,000 in fees.
• Additionally, Steeves acquired 495 Career Restricted Stock Units (RSUs) and 358 Career Restricted Stock Units (RSUs) in lieu of $86,000 in fees.
• The Career RSUs are fully vested immediately but will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service.
• Following these transactions, Steeves directly owns 1,564 stock options and 9,063 Career Restricted Stock Units.
• A power of attorney document confirms authorized representatives for SEC filings related to STERIS plc securities.

Sentiment

Score: 6

Explanation: The document is a neutral disclosure of insider transactions. The grants of stock options and RSUs could be viewed positively as aligning director interests with shareholders, but it's not a strong indicator of overall company performance.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.
• The issuance of stock options and RSUs in lieu of fees demonstrates a commitment to aligning director compensation with shareholder value.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency regarding the holdings and transactions of company directors.

Comparison to Industry Standards

• Director compensation packages often include stock options and restricted stock units to align their interests with those of shareholders.
• The vesting schedules and terms of these grants are generally consistent with industry practices for executive compensation.
• Companies like Medtronic and Boston Scientific also utilize similar equity-based compensation strategies for their directors.

Stakeholder Impact

• Shareholders may view the equity grants positively as aligning director interests with company performance.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates